Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports positive diabetes drug trial data

Novo Nordisk reports positive diabetes drug trial data

27th April 2010

Novo Nordisk has highlighted findings from a recent clinical trial which underlines the advantages of its diabetes treatment Victoza.

According to results published in the Lancet, type 2 diabetes patients trialled using Novo Nordisk’s human GLP-1 analogue showed a better response than a comparison group using the DPP-4 inhibitor treatment Januvia.

Victoza patients experienced greater reductions in HbA1c, fasting plasma glucose and body weight, while they were also more likely to report overall satisfaction with their treatment regime.

Dr Richard Pratley of the diabetes and metabolism translational medicine unit at the University of Vermont College of Medicine said: “With so many patients still struggling to lower their blood sugar, Victoza represents an effective new option.”

The drug has been approved in European nations since July 3rd 2009.

Earlier this month, Novo Nordisk announced the commencement of a new global survey of haemophilia patients, which is designed to collect data on the condition’s wider psychological and social impact.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.